IN2015MN00464A - - Google Patents
Info
- Publication number
- IN2015MN00464A IN2015MN00464A IN464MUN2015A IN2015MN00464A IN 2015MN00464 A IN2015MN00464 A IN 2015MN00464A IN 464MUN2015 A IN464MUN2015 A IN 464MUN2015A IN 2015MN00464 A IN2015MN00464 A IN 2015MN00464A
- Authority
- IN
- India
- Prior art keywords
- present
- chloro
- salt
- crystal
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012195761 | 2012-09-06 | ||
| PCT/JP2013/073865 WO2014038606A1 (ja) | 2012-09-06 | 2013-09-05 | ジスピロピロリジン誘導体の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00464A true IN2015MN00464A (enExample) | 2015-09-04 |
Family
ID=50237214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN464MUN2015 IN2015MN00464A (enExample) | 2012-09-06 | 2013-09-05 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US9359368B2 (enExample) |
| EP (1) | EP2894156B1 (enExample) |
| JP (1) | JP6016284B2 (enExample) |
| KR (1) | KR102217410B1 (enExample) |
| CN (1) | CN104812757B (enExample) |
| BR (1) | BR112015004816B1 (enExample) |
| CA (1) | CA2884238C (enExample) |
| ES (1) | ES2637150T3 (enExample) |
| IN (1) | IN2015MN00464A (enExample) |
| RU (1) | RU2647840C2 (enExample) |
| TW (1) | TWI586668B (enExample) |
| WO (1) | WO2014038606A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| HK1247204A1 (zh) | 2015-01-20 | 2018-09-21 | Arvinas Operations, Inc. | 用於雄激素受体的靶向降解的化合物和方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN107427501B (zh) * | 2015-02-20 | 2023-12-01 | 第一三共株式会社 | 通过联合使用治疗癌症的方法 |
| TWI697329B (zh) * | 2015-04-13 | 2020-07-01 | 日商第一三共股份有限公司 | 血液癌症治療用之醫藥及其用途 |
| EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| HK1253320A1 (zh) * | 2015-10-23 | 2019-06-14 | Daiichi Sankyo Company, Limited | 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法 |
| HK1253098A1 (zh) * | 2015-10-23 | 2019-06-06 | Daiichi Sankyo Company, Limited | 用於治疗癌症的mdm2抑制剂的给药方案 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| JP7286539B2 (ja) | 2016-11-01 | 2023-06-05 | アルビナス・オペレーションズ・インコーポレイテッド | タウタンパク質標的化ｐｒｏｔａｃ、および関連使用方法 |
| DK3689868T3 (da) | 2016-12-01 | 2024-01-02 | Arvinas Operations Inc | Tetrahydronaphthalen- og tetrahydroisoquinolinderivater som østrogenreceptordegraderende midler |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| AU2017382436C1 (en) | 2016-12-23 | 2021-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| JP2023539663A (ja) | 2020-08-28 | 2023-09-15 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| CN116390916A (zh) | 2020-09-14 | 2023-07-04 | 阿尔维纳斯运营股份有限公司 | 用于靶向降解雌激素受体的化合物的结晶形式 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| WO2024159164A2 (en) | 2023-01-26 | 2024-08-02 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979551B2 (en) | 2000-04-03 | 2005-12-27 | Rigel Pharmaceuticals, Inc. | Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents |
| US6740495B1 (en) | 2000-04-03 | 2004-05-25 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase assay |
| AU2002366278B2 (en) | 2001-12-18 | 2007-07-19 | F. Hoffmann-La Roche Ag | CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
| ES2307822T3 (es) | 2001-12-18 | 2008-12-01 | F. Hoffmann-La Roche Ag | Cis-imidazolinas como inhibidores de mdm2. |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| JP4814228B2 (ja) | 2004-05-18 | 2011-11-16 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ｃｉｓ−イミダゾリン |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| EP1856123B1 (en) * | 2005-02-22 | 2016-02-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| TW200801011A (en) * | 2006-02-07 | 2008-01-01 | Astrazeneca Ab | New compounds II |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| JP2009530236A (ja) | 2006-03-13 | 2009-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | スピロインドリノン誘導体 |
| WO2008036168A2 (en) | 2006-08-30 | 2008-03-27 | The Regents Of The University Of Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
| AU2007299130A1 (en) | 2006-09-21 | 2008-03-27 | F. Hoffmann-La Roche Ag | Oxindole derivatives as anticancer agents |
| US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| BRPI0810082A2 (pt) | 2007-03-29 | 2014-10-21 | Novartis Ag | 3-imidazolil-indóis para o tratamento de doenças proliferativas |
| US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US8134001B2 (en) | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US7723372B2 (en) | 2008-03-19 | 2010-05-25 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
| KR101380013B1 (ko) | 2008-09-18 | 2014-04-10 | 에프. 호프만-라 로슈 아게 | 치환 피롤리딘-2-카르복사미드 |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| DK2380892T3 (da) | 2009-01-16 | 2014-06-30 | Daiichi Sankyo Co Ltd | Imidazothiazolderivat med prolinringstruktur |
| US20100190814A1 (en) | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
| US7928233B2 (en) | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
| US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
| RU2553269C2 (ru) | 2009-11-12 | 2015-06-10 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Спирооксиндольные антагонисты mdm2 |
| US20110118283A1 (en) | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| RU2012147597A (ru) | 2010-04-09 | 2014-05-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| US20120010235A1 (en) | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| SG188459A1 (en) | 2010-09-08 | 2013-04-30 | Basf Se | Aqueous polishing compositions containing n-substituted diazenium dioxidesand/or n'-hydroxy-diazenium oxide salts |
| US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| US20120071499A1 (en) * | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
| WO2012076513A1 (en) | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
| TR201807311T4 (tr) | 2011-03-10 | 2018-06-21 | Daiichi Sankyo Co Ltd | Dispiropirolidin derivesi. |
| JP2014513699A (ja) | 2011-05-11 | 2014-06-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
-
2013
- 2013-09-04 TW TW102131754A patent/TWI586668B/zh active
- 2013-09-05 BR BR112015004816-1A patent/BR112015004816B1/pt active IP Right Grant
- 2013-09-05 KR KR1020157005386A patent/KR102217410B1/ko active Active
- 2013-09-05 IN IN464MUN2015 patent/IN2015MN00464A/en unknown
- 2013-09-05 EP EP13835941.9A patent/EP2894156B1/en active Active
- 2013-09-05 ES ES13835941.9T patent/ES2637150T3/es active Active
- 2013-09-05 RU RU2015112098A patent/RU2647840C2/ru active
- 2013-09-05 US US14/426,630 patent/US9359368B2/en active Active
- 2013-09-05 WO PCT/JP2013/073865 patent/WO2014038606A1/ja not_active Ceased
- 2013-09-05 CN CN201380057995.9A patent/CN104812757B/zh active Active
- 2013-09-05 CA CA2884238A patent/CA2884238C/en active Active
- 2013-09-05 JP JP2014534398A patent/JP6016284B2/ja active Active
-
2016
- 2016-05-02 US US15/144,485 patent/US9540386B2/en active Active
- 2016-12-06 US US15/370,292 patent/US9718830B2/en active Active
- 2016-12-06 US US15/370,380 patent/US9718831B2/en active Active
- 2016-12-06 US US15/370,618 patent/US9745315B2/en active Active
- 2016-12-06 US US15/370,160 patent/US9884871B2/en active Active
-
2018
- 2018-02-02 US US15/887,444 patent/US10023578B2/en active Active
- 2018-02-02 US US15/887,648 patent/US10030030B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015MN00464A (enExample) | ||
| PH12016500737B1 (en) | Process for the preparation of a pde4 inhibitor | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
| WO2014028597A3 (en) | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| AU2018260844A1 (en) | Processes of making and crystalline forms of a MDM2 inhibitor | |
| IN2014MN02459A (enExample) | ||
| EA201492204A1 (ru) | Нуклеозиды на основе урацила и спирооксетана | |
| PH12014502570A1 (en) | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] | |
| PH12015501964B1 (en) | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| WO2014028591A3 (en) | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2014MN00258A (enExample) | ||
| NZ603789A (en) | Heteroaryl compounds and methods of use thereof | |
| EA201171008A1 (ru) | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы | |
| MY170326A (en) | Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| IN2015DN01815A (enExample) | ||
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| MX2014012527A (es) | Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo. | |
| MX347241B (es) | Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa. | |
| AU2011286276A8 (en) | Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases | |
| MX2014000536A (es) | Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa. | |
| BR112015014869A2 (pt) | derivados de pirazolo-pirimidina terapeuticamente ativos | |
| MX347772B (es) | Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak. | |
| IN2015DN00345A (enExample) |